Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.45 |
| ▸ | UMPS | P11172 | 3/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | EIF4E | P06730 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809085 | 1.00 | FBP1 (0.49) | FBP1P2RY2UMPSDNPH1EIF4E | |
| SCHEMBL15836220 | 1.00 | FBP1 (0.49) | FBP1P2RY2UMPSDNPH1EIF4E | |
| SCHEMBL18118159 | 1.00 | FBP1 (0.49) | FBP1P2RY2UMPSDNPH1EIF4E | |
| SCHEMBL14928664 | 1.00 | FBP1 (0.49) | FBP1P2RY2UMPSDNPH1EIF4E | |
| SCHEMBL17789094 | 1.00 | FBP1 (0.49) | FBP1P2RY2UMPSDNPH1EIF4E | |
| SCHEMBL23906519 | 0.89 | P2RY2 (0.57) | P2RY2P2RY6 | |
| SCHEMBL18573959 | 0.89 | P2RY2 (0.57) | P2RY2P2RY6 | |
| SCHEMBL14853669 | 0.89 | P2RY2 (0.57) | P2RY2P2RY6 | |
| SCHEMBL19646631 | 0.88 | P2RY2 (0.39) | FBP1P2RY2UMPSDNPH1EIF4E | |
| SCHEMBL21082359 | 0.86 | P2RY2 (0.52) | P2RY2P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9192651-B2 | Modified polynucleotides for the production of secreted proteins | MODERNA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9095552-B2 | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | MODERNATX, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140105965-A1 | MODIFIED POLYNUCLEOTIDES ENCODING COPPER METABOLISM (MURR1) DOMAIN CONTAINING 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130259923-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | FBP1 1562/4885P2RY2 558/4885UMPS 36/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | FBP1 4459/4885P2RY2 1548/4885UMPS 220/4885 |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | FBP1 2989/4885P2RY2 3235/4885UMPS 357/4885 |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | POLRMT, RNMT, RNGTT | FBP1 1376/4885P2RY2 2414/4885UMPS 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.